EZH-301 (Sarcoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the study drug, tazemetostat (also called EPZ-6438) and to find out the effectiveness and best dose for people with STS.

What is the Condition Being Studied?

Soft-tissue sarcoma (STS), Advanced Epithelioid Sarcoma

Who Can Participate in the Study?

-Adults 18+
-Have a diagnosis of STS.

For more information on who can participate in this study please contact the study team.

Age Group
Adults

What is Involved?

If you choose to join this study you will:
-Have physical exams
-Give blood samples,
-Have an Electrocardiogram and echocardiogram (To look your heart activity)
-Take the study drug (Tazemetostat) by mouth twice a day.
-Get the study drug (Doxorubicin) though your vein drug on the first day of your drug cycle (21 day cycles) for a maximum of 6 cycles
-Complete follow-up visits or phone calls every 3 months for up to 2 years

Study Details

Full Title
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00105054
NCT: NCT04204941
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698